JP2014533733A5 - - Google Patents

Download PDF

Info

Publication number
JP2014533733A5
JP2014533733A5 JP2014543607A JP2014543607A JP2014533733A5 JP 2014533733 A5 JP2014533733 A5 JP 2014533733A5 JP 2014543607 A JP2014543607 A JP 2014543607A JP 2014543607 A JP2014543607 A JP 2014543607A JP 2014533733 A5 JP2014533733 A5 JP 2014533733A5
Authority
JP
Japan
Prior art keywords
composition
unit dosage
dosage form
item
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533733A (ja
JP5899327B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed filed Critical
Priority claimed from PCT/US2012/066605 external-priority patent/WO2013082003A1/en
Publication of JP2014533733A publication Critical patent/JP2014533733A/ja
Publication of JP2014533733A5 publication Critical patent/JP2014533733A5/ja
Application granted granted Critical
Publication of JP5899327B2 publication Critical patent/JP5899327B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543607A 2011-11-29 2012-11-27 Ｃ型肝炎ウイルスを処置するための組成物および方法 Active JP5899327B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
US61/564,500 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
USPCT/US2012/055621 2012-09-14
US201261707459P 2012-09-28 2012-09-28
US61/707,459 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus
US13/661,509 2012-10-26
PCT/US2012/066605 WO2013082003A1 (en) 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016007633A Division JP2016053096A (ja) 2011-11-29 2016-01-19 Ｃ型肝炎ウイルスを処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2014533733A JP2014533733A (ja) 2014-12-15
JP2014533733A5 true JP2014533733A5 (OSRAM) 2015-04-30
JP5899327B2 JP5899327B2 (ja) 2016-04-06

Family

ID=56291296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543607A Active JP5899327B2 (ja) 2011-11-29 2012-11-27 Ｃ型肝炎ウイルスを処置するための組成物および方法
JP2016007633A Withdrawn JP2016053096A (ja) 2011-11-29 2016-01-19 Ｃ型肝炎ウイルスを処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016007633A Withdrawn JP2016053096A (ja) 2011-11-29 2016-01-19 Ｃ型肝炎ウイルスを処置するための組成物および方法

Country Status (21)

Country Link
EP (2) EP3777867A1 (OSRAM)
JP (2) JP5899327B2 (OSRAM)
KR (1) KR101560994B1 (OSRAM)
CN (1) CN104039319B (OSRAM)
AR (1) AR089578A1 (OSRAM)
AU (1) AU2012346217B2 (OSRAM)
BR (1) BR112014012739A8 (OSRAM)
CA (1) CA2856529C (OSRAM)
CO (1) CO6970603A2 (OSRAM)
EA (1) EA027296B1 (OSRAM)
EC (1) ECSP14005678A (OSRAM)
ES (1) ES2817886T3 (OSRAM)
MD (1) MD4430C1 (OSRAM)
MX (1) MX2014006373A (OSRAM)
PE (1) PE20141296A1 (OSRAM)
PH (1) PH12014501133A1 (OSRAM)
SG (1) SG11201402609RA (OSRAM)
TW (1) TWI566773B (OSRAM)
UY (1) UY34474A (OSRAM)
WO (1) WO2013082003A1 (OSRAM)
ZA (1) ZA201404061B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800087T1 (it) 2011-09-16 2018-03-08 Gilead Pharmasset Llc Metodi per trattare hcv
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
WO2015132321A1 (en) * 2014-03-05 2015-09-11 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
SI3524234T1 (sl) 2014-06-13 2021-05-31 Ratiopharm Gmbh Trdne oblike sofosbuvira
EP2959891A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
EP2959901A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of sofosbuvir and ribavirin
WO2015197549A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
CN105267232A (zh) * 2014-06-30 2016-01-27 康普药业股份有限公司 一种用于治疗丙型肝炎的药物制剂及其制备方法
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
EP3203987A1 (en) * 2014-10-08 2017-08-16 Sandoz AG High drug load tablets comprising sofosbuvir
CN104546783A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种索非布韦薄膜包衣片制剂及其制备方法
CN104622836B (zh) * 2014-12-23 2020-02-21 浙江华海药业股份有限公司 索非布韦包衣片剂及其制备方法
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
WO2016156330A1 (en) * 2015-03-30 2016-10-06 Ratiopharm Gmbh Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid
CN104840964B (zh) * 2015-05-07 2018-01-16 南京正大天晴制药有限公司 一种稳定的索氟布韦药物组合物及其制备方法
CZ2015443A3 (cs) 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN104906062B (zh) * 2015-06-30 2018-05-25 浙江天顺生物科技有限公司 一种索非布韦的片剂及其制备方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
US20190185507A1 (en) 2016-08-19 2019-06-20 Sandoz Ag Sofosbuvir Derivatives for the Treatment of Hepatitis C
CZ2016553A3 (cs) 2016-09-09 2018-03-21 Zentiva, K.S. Pevná farmaceutická dávková forma obsahující sofosbuvir
CN106667936B (zh) * 2016-12-31 2021-02-05 江苏科本药业有限公司 一种索非布韦片剂及其制备方法
CN107041873B (zh) * 2017-02-17 2020-02-28 杭州青玥医药科技有限公司 索氟布韦包衣片剂的制备方法
CN106880642B (zh) * 2017-02-17 2019-08-06 杭州青玥医药科技有限公司 索氟布韦药物组合物及其制备方法
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN110604726B (zh) * 2019-07-19 2022-06-07 株洲千金药业股份有限公司 一种索非布韦组合物及其应用
CN111072742B (zh) * 2019-12-23 2022-12-02 南京正大天晴制药有限公司 一种治疗丙肝药物的新晶型及其组合物
CN111973566A (zh) * 2020-07-23 2020-11-24 石药集团中奇制药技术（石家庄）有限公司 一种索磷布韦片

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
JP2010519339A (ja) * 2007-02-26 2010-06-03 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖ複製阻害剤として有用な三級アミン置換ペプチド
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2699280A1 (en) 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
DE102008057284A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
CA2743912A1 (en) * 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
DE102009015702A1 (de) * 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) * 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US20110020272A1 (en) * 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
WO2011123668A2 (en) * 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype

Similar Documents

Publication Publication Date Title
JP2014533733A5 (OSRAM)
FI3804715T3 (fi) Farmaseuttinen yhdistelmä, koostumus ja yhdistelmävalmiste, joka käsittää glukokinaasin aktivaattorin ja dpp-iv:n estäjän ja niiden valmistusmenetelmä ja käyttö
RU2016122609A (ru) Составы соединений азаиндола
WO2009043448A3 (en) Neuromedin u-25 and neuromedin s as therapeutic agents
FI3265084T3 (fi) Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
RU2015110699A (ru) Фармацевтическая антиретровирусная композиция
JP2015524444A5 (OSRAM)
JP2016537347A5 (OSRAM)
WO2009043504A3 (en) Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer
WO2009039980A3 (en) Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection
JP2014515373A5 (OSRAM)
RU2004129324A (ru) Применения бисфосфоновых кислот для лечения и профилактики остеопороза
WO2009046832A3 (en) Short peptides used in medicine
JP7383715B2 (ja) アファビシン製剤、その作製方法及びその使用
WO2009033794A3 (en) Use of endothelin-1, optionally in combination with obestatin, as a therapeutic agent
MX2009003317A (es) Tabletas pediatricas de capecitabina.
RU2013154355A (ru) Способ лечения мезотелиомы ингибитором рi3к
RU2008119410A (ru) Диспергируемые таблетки, включающие деферасирокс
US20200179291A1 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
WO2009043479A3 (en) Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections
JP2020500168A5 (OSRAM)
JPWO2013031831A1 (ja) 関節リウマチなどの自己免疫疾患の治療の改善方法
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
ES2286716T3 (es) Composicion farmaceutica de liberacion controlada y proceso para preparar la misma.
EP3801532B1 (en) Formulations of raltegravir